Novavax Inc.’s lead product, the respiratory syncytial virus vaccine (RSV) ResVax, has missed its endpoints in its first Phase III trial, sending the firm’s share price tumbling by nearly 67% to close at $0.71 on NASDAQ on Feb. 28.
Top-line data show that the trial did not meet its primary objective of preventing medically significant RSV lower respiratory tract...